2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine | 1203655-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine
• 英文别名: (2,6-dichloro-pyrido[3,2-d]pyrimidin-4-yl)-(2,2,2-trifluoro-ethyl)-amine；(2,6-Dichloro-pyrido[3,2-d]pyrimidin-4-yl)-(2,2,2-trifluoro-ethyl)-amine
• CAS: 1203655-68-8
• 化学式: C₉H₅Cl₂F₃N₄
• 分子量: 297.067
• InChiKey: XRHOLSXYCCSCIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine 在 四(三苯基膦)钯 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 乙二醇二甲醚 、 水 为溶剂， 反应 18.0h， 生成 4-((6-(4-(1H-1,2,4-triazol-1-yl)phenyl)-4-(2,2,2-trifluoroethylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide
  参考文献：
  名称：

  Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors

  摘要：

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).

  DOI：

  10.1021/ml200163b
• 作为产物：
  描述：

  3-氨基-6-氯-2-吡啶羧酰胺 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.5h， 生成 2,6-dichloro-N-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidin-4-amine
  参考文献：
  名称：

  Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors

  摘要：

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).

  DOI：

  10.1021/ml200163b

文献信息

• [EN] 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS<br/>[FR] PYRIDO(3,2-D)PYRIMIDINES TRISUBSTITUÉES EN POSITION 2,4,6 UTILES POUR TRAITER DES INFECTIONS VIRALES
  申请人：GILEAD SCIENCES INC

  公开号：WO2010002998A1

  公开（公告）日：2010-01-07

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formuia (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  Pyrido(3,2-d)pyrimidine衍生物由结构式(Ia)表示：其中，R1、R2和R3在此处定义，其药用可接受的盐、立体化学异构体形式、N-氧化物、溶剂合物及其前药，用于治疗丙型肝炎。
• 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
  申请人：Canales Eda

  公开号：US20110123493A1

  公开（公告）日：2011-05-26

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (Ia): wherein, R 1 , R 2 and R 3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  该文描述了结构式(Ia)所代表的吡啶并[3,2-d]嘧啶衍生物：其中，R1、R2和R3在此定义，以及其药物可接受的加合盐、立体化学异构体形式、N-氧化物、溶剂化合物和前药，用于治疗丙型肝炎。
• 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
  申请人：Canales Eda

  公开号：US08536187B2

  公开（公告）日：2013-09-17

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  Pyrido(3,2-d)pyrimidine 衍生物的结构式(Ia)如下所示：其中，R1、R2和R3的定义见下文，其药学上可接受的加盐物、立体化学异构体形式、N-氧化物、溶剂化物和前药，用于治疗丙型肝炎。
• US8536187B2
  申请人：——

  公开号：US8536187B2

  公开（公告）日：2013-09-17
• Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors
  作者：Scott E. Lazerwith、Gina Bahador、Eda Canales、Guofeng Cheng、Lee Chong、Michael O. Clarke、Edward Doerffler、Eugene J. Eisenberg、Jaclyn Hayes、Bing Lu、Qi Liu、Mike Matles、Michael Mertzman、Michael L. Mitchell、Philip Morganelli、Bernard P. Murray、Margaret Robinson、Robert G. Strickley、Megan Tessler、Neeraj Tirunagari、Jianhong Wang、Yujin Wang、Jennifer R. Zhang、Xubin Zheng、Weidong Zhong、William J. Watkins

  DOI：10.1021/ml200163b

  日期：2011.10.13

  A novel series of HCV replication inhibitors based on a pyrido[3,2-d]primidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).